Parameter | Mean ± SD /Median [P25–P75] | Subgroups | n (%) | |
---|---|---|---|---|
T1D duration (years) | 27 ± 8.8 | 10–19 years | 8 (14.8) | |
20–29 years | 29 (53.7) | |||
 ≥ 30 years | 17 (31.5) | |||
Age at T1D onset (years) | 19 ± 10.1 | – | ||
BMI (kg/m2) | 25.4 ± 3.88 |  < 25.0 | 27 (50.0) | |
25.0–29.9 | 21 (38.9) | |||
 ≥ 30.0 | 6 (11.1) | |||
Insulin administration method | – | MDI | 39 (72.2) | |
CSII | 15 (27.8) | |||
Total daily dose of insulin (TDD; units) | 41 [34–75] | – | ||
Insulin sensitivity (= 1800/TDD) (mg/dL) | 45 ± 16.3 | |||
Routine point of care glucose measurement method | – | SMBG | 3 (5.6) | |
Flash CGM | 40 (74.1) | |||
Real-time CGM | 11 (20.4) | |||
Smoking | – | – | Currently (yes) | 4 (7.1) |
Previously (yes) | 18 (33.3) | |||
Pack years | 11 ± 7.7 | – | ||
Microvascular complications | – | Diabetic kidney disease (yes) | 18 (33.3) | |
– | Retinopathy (yes) | 24 (44.4) | ||
Lipid profile (mg/dL) | TC | 170 ± 26.5 | – | |
HDL-C | 59 ± 14.0 | |||
LDL-C | 95 ± 21.1 | |||
TGL | 68 [54.5–90.8] | |||
24-h ABPM (mmHg) | 24-h SBP/DBP | 119/73 ± 10.7/6.2 | – | |
Daytime SBP/DBP | 124/76 ± 11.8/6.6 | |||
Night-time SBP/DBP | 109/64 ± 10.0/6.2 |